Wrinkles

... PharmaLive: Preserving Competition, FTC Requires Divestiture Before Allowing Allergan’s Acquisition of Inamed BUSINESS STRATEGY Preserving Competition, FTC Requires Divestiture Before Allowing Allergan’s Acquisition of Inamed Consent Order Requires Allergan to Divest Future Botox Rival Reloxin in $3.2 Billion Deal WASHINGTON, March 8, 2006-Botox marketer Allergan, Inc., and the Inamed Corporation will divest the rights to develop and distribute Reloxin, a potential Botox rival, to settle Federal Trade Commission charges that Allergan’s $3.2 billion purchase of Inamed would violate federal antitrust laws.

The FTC alleges that Allergan’s purchase of the expected first serious competitor to Botox likely would reduce competition and force consumers to pay higher prices for the botulinum toxin type A products used by millions of Americans to temporarily erase frown lines and wrinkles.

Under the terms of the FTC settlement, the companies will return the development and distribution rights to Reloxin to Ipsen Ltd., its U.K.-based manufacturer.

On December 20, 2005, Allergan reached an agreement to acquire Inamed for approximately $3.2 billion.

Allergan’s Botox is the best-selling botulinum toxin in the United States and the only such product approved by the U.S.

Food and Drug Administration for the treatment of facial wrinkles.

In 2002, Inamed acquired the U.S.

rights to a rival botulinum toxin type A, Reloxin, from Ipsen.

Reloxin currently is in Phase III ...

Read more...